| Right of use assets |
Schedule of right of use assets
| | |
2026 | | |
2026 | | |
2025 | |
| | |
US$ | | |
S$ | | |
S$ | |
| | |
| | |
| | |
| |
| Cost | |
| | | |
| | | |
| | |
| At beginning of financial year | |
| 6,809,333 | | |
| 8,660,790 | | |
| 2,753,093 | |
| Additions | |
| 3,222,725 | | |
| 4,170,528 | | |
| 3,275,940 | |
| Acquisition | |
| - | | |
| - | | |
| 4,825,203 | |
| Depreciation | |
| | | |
| | | |
| | |
| Written off | |
| (836,610 | ) | |
| (1,073,896 | ) | |
| (3,966,296 | ) |
| Fair value reserve | |
| - | | |
| - | | |
| 1,772,850 | |
| Currency translation differences | |
| (110,043 | ) | |
| - | | |
| - | |
| At end of financial year | |
| 9,085,405 | | |
| 11,757,422 | | |
| 8,660,790 | |
| | |
| | | |
| | | |
| | |
| Accumulated Depreciation | |
| | | |
| | | |
| | |
| At beginning of financial year | |
| 2,918,011 | | |
| 3,711,418 | | |
| 2,729,633 | |
| Acquisition | |
| - | | |
| - | | |
| 3,691,417 | |
| Depreciation | |
| 2,761,485 | | |
| 3,544,719 | | |
| 1,073,469 | |
| Written off | |
| (632,728 | ) | |
| (812,187 | ) | |
| (3,783,101 | ) |
| Currency translation differences | |
| (67,284 | ) | |
| - | | |
| - | |
| At end of financial year | |
| 4,979,484 | | |
| 6,443,950 | | |
| 3,711,418 | |
| | |
| | | |
| | | |
| | |
| Carrying amount | |
| 4,105,921 | | |
| 5,313,472 | | |
| 4,949,372 | |
| At end of financial year | |
| 4,105,921 | | |
| 5,313,472 | | |
| 4,949,372 | |
Basel
Medical Group Ltd. and its Subsidiaries
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
For
year ended June 30, 2026 and 2025
|